Development and Evaluation of Computerized Olfactory Training Program (COT) for Cognitive Decline in Early Alzheimer's Disease

针对早期阿尔茨海默病认知衰退的计算机嗅觉训练计划 (COT) 的开发和评估

• 批准号: 10614897
• 负责人: Charles Chiedu Nwaokobia
• 金额: $ 9.83万
• 依托单位: EVON MEDICS, LLC
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10614897
• 关键词: Acute; Administrative Supplement; African American population; Aging; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Amyloid; Amyloid beta-Protein; Anabolism; Animals; Base of the Brain; Behavior Therapy; Behavioral; Black Populations; Brain; Brain region; Businesses; Caregiver Burden; Caring; Certification; Clinical; Clinical Research; Clinical Trials; Cognitive; Communities; Dementia; Development; Devices; Disease; Disease Progression; Early Intervention; Early identification; Educational Materials; Effectiveness; Emotional; Ensure; Entrepreneurship; Environment; Evaluation; Exposure to; Functional disorder; Future; Generations; Goals; Government; Health care facility; Healthcare; Hippocampus (Brain); Home; Human; Human Subject Research; Impaired cognition; Individual; Industry; Internships; Intervention; Intervention Studies; Intervention Trial; Investigation; Knowledge; Lead; Leadership; Marketing; Maryland; Medical; Mentors; Minority; Minority Groups; Modification; Multimedia; Neurosciences; Odors; Olfactory Cortex; Olfactory Pathways; Participant; Pathologic; Patient Recruitments; Patients; Performance; Persons; Phase; Phase II Clinical Trials; Phase III Clinical Trials; Plant Roots; Plants; Policies; Population; Prevention; Primary Health Care; Principal Investigator; Process; Provider; Psychophysics; Public Health; Randomized Clinical Trials; Recommendation; Recording of previous events; Regimen; Research; Research Personnel; Resources; Safety; Sampling; Site; Sleep disturbances; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Solid; Stimulant; Structure; System; Therapeutic; Therapeutic Intervention; Time; Training; Training Programs; Translating; Translations; Underrepresented Minority; United States; Universities; Ursidae Family; Visit; abeta accumulation; advanced dementia; apolipoprotein E-4; base; career; cerebral atrophy; cognitive function; cognitive training; cohort; comorbidity; computerized; cost; distrust; early phase clinical trial; effectiveness implementation study; efficacy study; entorhinal cortex; ethnic minority; experience; feasibility trial; follow-up; habituation; hands on research; health literacy; improved; innovation; intervention program; member; mild cognitive impairment; minority communities; minority student; neurofilament; novel; portability; prevent; preventive intervention; programs; recruit; research and development; research study; resilience; satisfaction; screening; skills; skills training; social stigma; stimulant use; success; therapeutic target; user-friendly

ABSTRACT We propose to evaluate and optimize the portable, home-based product – the Computerized Olfactory Training Program (COT) – as a disease modifying intervention for prevention of progressive cognitive decline and progressive dementia in early Alzheimer's Disease (AD). The COT uses validated neuroprotective olfactory stimulants to intensely engage the primary and secondary olfactory cortices, with stimulation parameters that overcome olfactory habituation, paired with computerized olfactory cognitive training tasks that synergistically enhance the same brain regions; with the goal of increasing structural and functional resilience to AD progression. Phase I research and development met or exceeded stated technical milestones: COT intervention led to increased olfactory and cognitive functions 6 and 12 months later in ApoE4 carriers with mild cognitive impairment and early dementia. Among completers of 12-month follow-up visit, COT blunted trajectory in shrinkage of the entorhinal cortex and the hippocampus. Furthermore, the acute effects of odorant molecules in the COT in regulating sleep disruptions and emotional reactivity adds to a potential value of COT for treatment of behavioral dysfunctions in advanced AD. Alzheimer’s disease is a major public health crisis both in the United States and worldwide. Hitherto, no therapeutic has demonstrated significant effectiveness in modifying progression from early stages to advanced stages of AD. Most putative disease modifying therapeutics targeting various steps of amyloid biosynthesis and amyloid beta (Aβ) accumulation have either failed to reverse cognitive decline or worsened cognitive decline in Phase III clinical trials. However, neuroscience evidence that AD pathology progresses early, over several decades in the olfactory brain regions, before emergence of progressive, irreversible cognitive decline and dementia, as well as experimental and clinical findings that olfactory compromise accelerates the progression of AD, provide solid premise for targeting olfactory structure and function in the modification of AD progression. The success of use of enriched odor environment in reducing aggregation of pathological neurofilaments in animals spurred high hopes for translation of olfactory training (OT) into treatment of AD in humans. Unfortunately, lack of innovative approaches to sustain olfactory engagement sufficiently to influence functional and structural plasticity in clinical populations, hindered the translation of OT into an AD intervention. We built an innovative olfactory treatment delivery system for home use; established a proprietary regimen of safe neuroprotective plant odorant extracts and stimulation parameters that overcome odorant habituation in the primary olfactory cortex; and created a synchronized App to simultaneously administer olfactory cognitive training tasks that synergistically target the same brain regions being stimulated by the odorants. This breakthrough product, the COT showed excellent promise in reversing cognitive decline in our Phase I SBIR. Key technical objectives of this Phase II project are to: (1) demonstrate COT efficacy for prevention of brain atrophy and cognitive decline in a powered randomized clinical trial of early dementia; (2) validate its safety; (3) further configure the platform for user-friendliness, portability for home use, acceptability and marketing; and (4) explore new indications for treating behavioral disturbances in people with moderate to advanced dementia, in an effort to reduce care- giver burden. Upon completion of Phase II, we will be poised to expand the research to Phase III efficacy study, or an implementation study of effectiveness in the real-world setting through commercial partnerships developed over the course of this project. To the best of our knowledge, this will be the first evaluation of a home-based, scalable, computerized, chemosensory-based brain stimulation for disease modification in AD.

抽象的 我们建议评估和优化便携式家用产品——计算机化嗅觉训练 计划（COT）——作为一种疾病改变干预措施，用于预防进行性认知衰退和 早期阿尔茨海默病 (AD) 中的进行性痴呆。 COT 使用经过验证的神经保护嗅觉 刺激剂强烈刺激初级和次级嗅觉皮层，刺激参数为 克服嗅觉习惯，配合计算机化的嗅觉认知训练任务，协同作用 增强相同的大脑区域；目标是增强 AD 的结构和功能恢复能力 进展。第一阶段的研发达到或超过了规定的技术里程碑：COT 6 个月和 12 个月后，干预导致轻度 ApoE4 携带者的嗅觉和认知功能增强 认知障碍和早期痴呆。在完成 12 个月随访的患者中，COT 减弱 内嗅皮层和海马体收缩的轨迹。此外，气味剂的急性影响 COT 中调节睡眠中断和情绪反应的分子增加了 COT 的潜在价值 用于治疗晚期 AD 的行为功能障碍。阿尔茨海默病是一场重大的公共卫生危机 在美国和世界各地。迄今为止，尚无治疗方法显示出显着的疗效 改变 AD 从早期阶段到晚期阶段的进展。最公认的疾病改变 针对淀粉样蛋白生物合成和淀粉样蛋白 β (Aβ) 积累的各个步骤的疗法具有以下任一特征： 在 III 期临床试验中未能逆转认知能力下降或认知能力下降恶化。然而， 神经科学证据表明，AD 病理学在嗅觉大脑中的早期进展持续了数十年 区域，在出现进行性、不可逆转的认知衰退和痴呆之前，以及实验性的 以及嗅觉损害加速 AD 进展的临床发现，为 针对改变 AD 进展的嗅觉结构和功能。丰富使用成功 气味环境在减少动物病理性神经丝聚集方面引起了人们的厚望 将嗅觉训练 (OT) 转化为人类 AD 的治疗。遗憾的是缺乏创新 充分维持嗅觉参与以影响功能和结构可塑性的方法 临床人群，阻碍了 OT 转化为 AD 干预措施。我们建立了一个创新的嗅觉 家庭使用的治疗输送系统；建立了安全神经保护植物的专有方案 克服初级嗅皮层气味习惯的气味提取物和刺激参数； 并创建了一个同步应用程序来同时管理嗅觉认知训练任务 协同作用于受气味剂刺激的相同大脑区域。这一突破性产品， 在我们的第一阶段 SBIR 中，COT 在逆转认知能力下降方面表现出了良好的前景。关键技术目标 该二期项目的目标是：（1）证明COT对于预防脑萎缩和认知能力下降的功效 早期痴呆症的有力随机临床试验； (2)验证其安全性； (3)进一步配置平台 用户友好性、家庭使用的便携性、可接受性和营销； (4)探索新的适应症 治疗中度至晚期痴呆症患者的行为障碍，以减少护理费用 给予者的负担。 II 期完成后，我们将准备将研究扩展到 III 期疗效 研究，或通过商业伙伴关系在现实世界中进行有效性的实施研究 是在该项目的过程中开发的。据我们所知，这将是对 以家庭为基础的、可扩展的、计算机化的、基于化学感应的脑刺激，用于治疗 AD 疾病。